SEARCH

Current Edition

AstraZeneca

AstraZeneca wagers $200M on Ionis’ next chance at a rare disease drug

AstraZeneca is betting that Ionis’ second drug for transthyretin amyloidosis, or ATTR, will stand out where its first one couldn’t. Ionis developed Tegsedi for years …

Continue Reading →